Recombinant human insulin was one of the first products of biotechnology. It was developed in response to the need for a consistent and sufficient worldwide supply. Recombinant human insulin replaced the animal insulins and semisynthetic insulins obtained by modification of animal insulins. Bioequivalence studies were required for regulatory approval.
became available in limited quantities by modification of animal insulins. [1] [2] [3] [4] This development was based on identification of the structure of human insulin from human autopsy material. Reference material was obtained by total chemical synthesis and by small quantities of purified human insulin extracted from autopsy material. 5 A more efficient solution to provide human insulin of high purity and increased quantity became available when recombinant DNA technology was applied to biosynthesis of human insulin on an industrial scale. 6, 7 The genetic information for a proinsulin fusion protein was inserted into bacteria (Escherichia coli) or in yeast (Saccharomyces cerevisiae, Pichia pastoris). Post-translational processing and extensive purification of the final drug product obtained biologically active human insulin. A process for recombinant human insulin was initiated by Genentech in 1978, 8 and production at an industrial scale was developed by Eli Lilly. 9, 10 The company obtained marketing authorisation in the US and European countries in 1982 (Humulin ® ) for a drug product produced in E. coli. NovoNordisk obtained marketing authorisation in 1991 for a recombinant human insulin produced by a different process of biosynthesis in yeast. [11] [12] [13] Brand names at that time were Novolin ® in the US and Actrapid ® , Protaphane ® and Mixtard ® in Europe (see Table   1 ). Another method for recombinant human insulin in yeast (P. pastoris) was described later. 14, 15 Sanofi developed recombinant human insulin (drug substance) in 1995 using the E. coli process and obtained marketing approval for the insulin formulations in 1997 (Insuman ® ).
In each case, recombinant human insulin replaced the previously produced semisynthetic animal insulins. The change required a prolonged test period for the bioequivalence of the new insulin formulations based on recombinant human, 16, 17 comparing them with semisynthetic human insulin obtained by modification of animal insulins. 9 Bioequivalence was established by clinical pharmacology studies in healthy volunteers (phase I) using the insulin clamp procedure. 18 In subsequent clinical studies, patients with diabetes were safely and effectively transferred from semisynthetic human insulin to recombinant human insulin, with no change in insulin dose range. [19] [20] [21] There was a prolonged period of discussion about differential responses in perception of hypoglycaemia, 22 a debate that required specific studies to resolve this controversy. three originators (see Table 1 ). The current regulatory process for drug approval of insulin formulations requires bioequivalence studies (phase II) comparing a marketed insulin product (reference compound) with a new product developed by a different company. 24 The insulin drug substance (active pharmaceutical ingredient) is processed to formulations addressed as regular human insulin (short acting), human neutral 
Biotechnology of Human Insulin Production
Production of recombinant human insulin starts with the insertion of a gene encoding the precursor protein pre-pro-insulin into a DNA 
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Biosynthetic human proinsulin vector that is transferred into a host (see Figure 1) . 25 During the product synthesis, the culture and fermentation conditions are controlled tightly to optimise yields. 26 A fusion protein obtained by fermentation is converted to bioactive human insulin by post-translational processing. 27 The final step in the manufacturing process is the multi-step purification of human insulin until the necessary high extent of purification is obtained (see Figures 2A and 2B ). This is followed by crystallisation of the final product and pharmaceutical manufacture of the different insulin products (see Figures 1 and 2B ).
Biosynthetic human insulin
The process of obtaining human insulin by biosynthesis was subsequently adapted for production of insulin analogues with modified amino acid sequence and different time-action profiles (see Table 1 ).
Insulin analogues are manufactured in a similar process by biosynthesis There are options of using a vial and syringe (at low cost) or patient-convenient technology using insulin pens that contain a cartridge (replaceable) and more advanced insulin pens that are disposable after use. 38, 39 Patients need to be informed about specific aspects of insulin injection. 40 The insulin pens have now reached a level of clinical convenience and reliability that makes them the preferred application system. 38 For the Insuman injection, for example, different types of pens are available such as SoloStar (disposable) and AllStar, a re-usable pen affordable for developing countries. An initial period of monitoring after the change is recommended, to establish that glycaemic control remains unchanged, despite change of the human insulin product. 40 This is of particular relevance for premixed and NPH-insulins, because the time-action profile may change more than for a regular insulin formulation. Clinical consideration and careful monitoring is even more advised when changing from a human insulin formulation to an insulin analogue. Reasons for the change may be the requirement for more rapid absorption before a meal (rapid-acting insulin analogues), a more balanced basal insulin profile with extended duration (long-acting insulin analogues) and reduced frequency of injections. In each of these instances -when changing to a different insulin -the rate and extent of absorption will change and an extended glucose monitoring is essential after the change.
Outlook for Therapy with Recombinant Human Insulin
For many years, recombinant human insulin has been the standard 
